Literature DB >> 9916091

Regulatory T cells in the antibody response to Haemophilus influenzae type b polysaccharide.

M A Breukels1, G T Rijkers, M M Voorhorst-Ogink, B J Zegers.   

Abstract

An in vitro culture system for the induction of an antipolysaccharide response was used to study the cellular interactions which determine the magnitude and nature of this B-lymphocyte response. Healthy adult volunteers were vaccinated with the Haemophilus influenzae type b polysaccharide (PRP)-tetanus toxoid (TT) conjugate vaccine. Optimal in vitro anti-PRP and anti-TT antibody responses were obtained when B cells were cultured with equal amounts of T cells. The in vitro response is antigen dependent and antigen specific. Culturing with PRP mixed with TT in the presence of T cells induces the highest number of anti-PRP antibody-secreting cells (ASC) (128.4 x// 15.9 [geometric mean x// standard deviation] immunoglobulin M [IgM] anti-PRP ASC/10(6) cells; 9.3 x// 7.6 IgG anti-PRP ASC/10(6) cells). Culturing without T cells induced no anti-PRP ASC; culturing with only PRP, in the presence of T cells, yielded low numbers of anti-PRP ASC (3.7 x// 5.2 IgM anti-PRP ASC/10(6) cells and 1.2 x// 2.2 IgG anti-PRP ASC/10(6) cells). Transwell studies showed that the requirements for the antibody response against the polysaccharide are different from those of an antiprotein response. Cytokines formed as a consequence of contact between protein-specific B and T cells were on their own not sufficient to activate TT-specific B cells (8.4 x// 1.4 anti-TT ASC/10(6) cells); direct contact between T and B cells appeared to be an absolute requirement. However, physical contact between B and T cells in one compartment of the Transwell system resulted in the release of soluble factors able to stimulate B cells in the other compartment to secrete antipolysaccharide antibodies (164 x// 1.6 anti-PRP ASC/10(6) cells).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9916091      PMCID: PMC96387     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

1.  A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease.

Authors:  J Eskola; H Käyhty; A K Takala; H Peltola; P R Rönnberg; E Kela; E Pekkanen; P H McVerry; P H Mäkelä
Journal:  N Engl J Med       Date:  1990-11-15       Impact factor: 91.245

Review 2.  CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation.

Authors:  R J Noelle; J A Ledbetter; A Aruffo
Journal:  Immunol Today       Date:  1992-11

Review 3.  T cell regulation of the antibody response to bacterial polysaccharide antigens: an examination of some general characteristics and their implications.

Authors:  P J Baker
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

4.  Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells.

Authors:  P Panina-Bordignon; A Tan; A Termijtelen; S Demotz; G Corradin; A Lanzavecchia
Journal:  Eur J Immunol       Date:  1989-12       Impact factor: 5.532

5.  Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group.

Authors:  S B Black; H R Shinefield; B Fireman; R Hiatt; M Polen; E Vittinghoff
Journal:  Pediatr Infect Dis J       Date:  1991-02       Impact factor: 2.129

6.  Splenic dependence of the antibody response to thymus-independent (TI-2) antigens.

Authors:  P L Amlot; D Grennan; J H Humphrey
Journal:  Eur J Immunol       Date:  1985-05       Impact factor: 5.532

7.  Antibody levels achieved in infants by course of Haemophilus influenzae type B polysaccharide/diphtheria toxoid conjugate vaccine.

Authors:  J Eskola; H Käyhty; H Peltola; V Karanko; P H Mäkelä; J Samuelson; L K Gordon
Journal:  Lancet       Date:  1985-05-25       Impact factor: 79.321

Review 8.  Pneumococcal polysaccharide vaccines.

Authors:  R Austrian
Journal:  Rev Infect Dis       Date:  1989 May-Jun

9.  In vitro induction of a Haemophilus influenzae type b polysaccharide-specific antibody response in human peripheral blood lymphocytes of individuals recently vaccinated with an oligosaccharide-protein conjugate.

Authors:  C C Peeters; A M Tenbergen-Meekes; C J Heijnen; J T Poolman; B J Zegers; G T Rijkers
Journal:  J Immunol       Date:  1991-12-15       Impact factor: 5.422

10.  Pneumococcal polysaccharides complexed with C3d bind to human B lymphocytes via complement receptor type 2.

Authors:  A W Griffioen; G T Rijkers; P Janssens-Korpela; B J Zegers
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

View more
  5 in total

1.  Immune response to Haemophilus influenzae type b vaccination in patients with chronic renal failure.

Authors:  Nicole Hawdon; Eli B Nix; Raymond S W Tsang; Garry Ferroni; William G McCready; Marina Ulanova
Journal:  Clin Vaccine Immunol       Date:  2012-04-25

Review 2.  Antibody repertoires in infants and adults: effects of T-independent and T-dependent immunizations.

Authors:  E E Adderson
Journal:  Springer Semin Immunopathol       Date:  2001-12

3.  Pneumococcal conjugate vaccines overcome splenic dependency of antibody response to pneumococcal polysaccharides.

Authors:  M A Breukels; A Zandvoort; G P van Den Dobbelsteen; A van Den Muijsenberg; M E Lodewijk; M Beurret; P A Klok; W Timens; G T Rijkers
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

Review 4.  Haemophilus influenzae type b conjugate vaccines.

Authors:  Dominic F Kelly; E Richard Moxon; Andrew J Pollard
Journal:  Immunology       Date:  2004-10       Impact factor: 7.397

5.  Dendritic cells pulsed with intact Streptococcus pneumoniae elicit both protein- and polysaccharide-specific immunoglobulin isotype responses in vivo through distinct mechanisms.

Authors:  Jesus Colino; Yi Shen; Clifford M Snapper
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.